VCAM1 Expression in Glioma: Mouse Model and Clinical Survival Data

A research paper published on figshare in 2026 analyzes VCAM1 expression in glioma. It includes data from human glioma datasets correlated with patient survival and from syngeneic and primary mouse glioma models. The author is Jiajing Dai.

Use Cases

• Correlating VCAM1 expression with patient survival outcomes based on clinical data mentioned in the description
• Analyzing VCAM1 expression patterns in tumor and stromal cell populations based on mouse model data
• Evaluating the therapeutic impact of targeting astrocytic VCAM1 on tumor growth and survival based on ablation experiments
• Investigating tumor heterogeneity by comparing VCAM1 efficacy across different tumor locations and genetic backgrounds

Strengths

• Includes specific co-expression percentages for VCAM1 with markers like SOX2 (86.5%), CD133 (86.3%), and Ki67 (93.4%)
• Provides concrete survival data from mouse models, such as median survival extension from 52 to 66.5 days
• Correlates findings with clinical data on VCAM1 expression and survival in low-grade glioma patients

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The dataset is a 1.4 MB PDF, likely containing textual analysis rather than raw structured data

Provenance

Source

figshare

Collection Method

Analysis of human glioma datasets and experimental mouse models.

Freshness

Last updated 2026-04-24 04:22:58; freshness should be verified